Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
5 April 2021 |
Main ID: |
EUCTR2019-001698-10-CY |
Date of registration:
|
11/09/2020 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study to determine the effectiveness and safety of ION-682884 in patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
|
Scientific title:
|
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy - NEURO – TTRANSFORM |
Date of first enrolment:
|
24/09/2020 |
Target sample size:
|
140 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001698-10 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: no Cross over: yes Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
Chile
|
China
|
Colombia
|
Cyprus
|
Estonia
|
France
|
Germany
|
Greece
|
Ireland
|
Israel
|
Italy
|
Japan
|
Korea, Democratic People's Republic of
|
Latvia
|
Malaysia
|
Mexico
|
Netherlands
|
New Zealand
|
Portugal
|
Spain
|
Sweden
|
Switzerland
|
Taiwan
|
Turkey
|
United Kingdom
| |
Contacts
|
Name:
|
Ionis Clinical Trial Information
|
Address:
|
2855 Gazelle Court
CA 92010
Carlsbad
United States |
Telephone:
|
+1760931 9200 |
Email:
|
ClinicalTrials@ionisph.com |
Affiliation:
|
Ionis Pharmaceuticals, Inc. |
|
Name:
|
Ionis Clinical Trial Information
|
Address:
|
2855 Gazelle Court
CA 92010
Carlsbad
United States |
Telephone:
|
+1760931 9200 |
Email:
|
ClinicalTrials@ionisph.com |
Affiliation:
|
Ionis Pharmaceuticals, Inc. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Aged 18 to 82 years at the time of informed consent 2. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal 3. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the subject or the subject's non-pregnant female partner must be using a highly effective contraceptive method 4. Diagnosis of hereditary transthyretin-mediated polyneuropathy as defined by meeting all 3 of the following: • Stage 1 or Stage 2 FAP • Documented genetic mutation in the TTR gene • Symptoms and signs consistent with polyneuropathy as measured by NIS score = 10 and = 130 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 86 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 54
Exclusion criteria: 1. Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a subject unsuitable for inclusion, including but not limited to abnormal safety labs 2. Karnofsky performance status = 50 3. Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease), including uncontrolled diabetes 4. Prior liver transplant or anticipated liver transplant within 1-yr of Screening 5. New York Heart Association (NYHA) functional classification of = 3 6. Acute coronary syndrome or major surgery within 3 months of Screening 7. Other types of amyloidosis 8. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study 9. Current treatment with any approved drug for hereditary TTR amyloidosis such as Vyndaqel® / Vyndamax™ (tafamidis), Tegsedi™ (inotersen), Onpattro™ (patisiran),off-label use of diflunisal or doxycycline, and tauroursodeoxycholic acid (TUDCA).If previously treated with Vyndaqel® / Vyndamax™, diflunisal or doxycycline, and TUDCA, must have discontinued treatment for 2 weeks prior to Study Day 1 10. Previous treatment with TegsediTM (Inotersen) or OnpattroTM (patisiran), or other oligonucleotide or RNA therapeutic (including siRNA)
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy MedDRA version: 20.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
|
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|
Intervention(s)
|
Product Name: ION-682884 Product Code: ION-682884 Pharmaceutical Form: Solution for injection INN or Proposed INN: ION-682884 CAS Number: 1637600-16-8 Current Sponsor code: ION-682884 Other descriptive name: ION-682884 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-
Product Name: inotersen Product Code: ISIS 420915 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: INOTERSEN CAS Number: 1432726-13-0 Current Sponsor code: ISIS 420915 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200-
|
Primary Outcome(s)
|
Primary end point(s): Interim Analysis Co-Primary Efficacy Endpoints at Week 35 - Percent change from Baseline in serum TTR concentration - Change from Baseline in mNIS+7
Final Analysis Co-Primary Efficacy Endpoints - Percent change from Baseline in serum TTR concentration - Change from Baseline in mNIS+7 - Change from Baseline in Norfolk QOL-DN
|
Timepoint(s) of evaluation of this end point: Interim Analysis Co-Primary Efficacy Endpoints at Week 35 Final Analysis Co-Primary Efficacy Endpoints - Percent change from Baseline in serum TTR concentration at Week 65 - Change from Baseline in mNIS+7 at Week 66 - Change from Baseline in Norfolk QOL-DN at Week 66
|
Secondary Objective: To evaluate the efficacy of ION-682884, as compared to the placebo cohort in the NEURO-TTR trial, based on the change from Baseline in the following measures: - Neuropathy Symptom and Change Score (NSC) - Physical component summary (PCS) score of 36-Item Short Form Survey (SF-36) - Polyneuropathy disability (PND) score - Modified body mass index (mBMI)
|
Main Objective: To evaluate the efficacy of ION-682884 after administration for 65 weeks, as compared to the historical control of the placebo cohort in the NEURO-TTR trial, based on the change from Baseline in serum TTR concentration, mNIS+7 and in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN) in patients with hATTR.
|
Secondary Outcome(s)
|
Secondary end point(s): Interim Analysis Key Secondary Efficacy Endpoint at Week 35 - Change from Baseline in Norfolk QOL-DN Final Analysis Secondary Endpoint - Change from Baseline in Norfolk QOL-DN - Change from Baseline in the PCS score of SF-36 - Change from Baseline in PND score - Change from Baseline in mBMI Interim Analysis Key Secondary Efficacy Endpoint at Week 35 Change from Baseline in NSC at Weeks 35 and 66 Change from Baseline in the PCS score of SF-36 at Week 65 Change from Baseline in PND score at Week 65 Change from Baseline in mBMI at Week 65
|
Timepoint(s) of evaluation of this end point: Interim Analysis Key Secondary Efficacy Endpoint at Week 35
Change from Baseline in NSC at Weeks 35 and 66 Change from Baseline in the PCS score of SF-36 at Week 65 Change from Baseline in PND score at Week 65 Change from Baseline in mBMI at Week 65
|
Secondary ID(s)
|
ION-682884-CS3
|
2019-001698-10-GB
|
Source(s) of Monetary Support
|
Ionis Pharmaceuticals, Inc.
|
Ethics review
|
Status: Approved
Approval date: 24/09/2020
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|